Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 6/20 | 0.83 |
| ▸ | RORC | P51449 | 5/20 | 0.83 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.83 |
| ▸ | USP2 | O75604 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.83 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.83 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.71 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.71 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.71 |
| ▸ | CRYAB | P02511 | 1/20 | 0.68 |
| ▸ | HMGCR | P04035 | 1/20 | 0.68 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.68 |
| ▸ | ITGAV | P06756 | 1/20 | 0.68 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.68 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.68 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | F2 | P00734 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL3209061 | 1.00 | OSBP (0.83) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL4661902 | 1.00 | OSBP (0.83) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL28419656 | 1.00 | OSBP (0.83) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL4661901 | 1.00 | OSBP (0.83) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL28077325 | 0.98 | OSBP (0.83) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL27651839 | 0.97 | OSBP (0.78) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL28097544 | 0.97 | OSBP (0.89) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL27624441 | 0.96 | OSBP (0.91) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL27968992 | 0.95 | OSBP (0.93) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL18049020 | 0.93 | OSBP (0.93) | OSBPRORCOSBP2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168002-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021257736-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2021-12-23 | — | — | WO | disclosed |
| CN-111787908-A | Method for producing lipid carrier | 以因塔师健康有限责任公司名义经营的尼克劳斯·A·费可瑞斯有限责任公司 | 2020-10-16 | — | — | CN | disclosed |
| US-8846078-B2 | Brucellosis DNA vaccine | THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD & RURAL AFFAIRS ACTING THROUGH THE ANIMAL HEALTH AND VETERINARY LABORATORIES AGENCY (GB) | 2014-09-30 | — | — | US | disclosed |
| US-7678790-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2008000777-A2 | PHENYL- PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| US-20070224257-A1 | BRUCELLOSIS DNA VACCINE | THE SECRETARY OF STATE FOR ENVIRONMENT, FOODS & RURAL AFFAIRS (GB) | 2007-09-27 | — | — | US | disclosed |
| US-20070155719-A1 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1802278-A2 | DERMAL DELIVERY OF N-METHYL-GLUCAMINE AND N-METHYL-GLUCAMINE COMPOUNDS | Dynamis Therapeutics, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060110439-A1 | Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds | DYNAMIS THERAPEUTICS, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2006047409-A2 | DERMAL DELIVERY OF N-METHYL-GLUCAMINE AND N-METHYL-GLUCAMINE COMPOUNDS | DYNAMIS THERAPEUTICS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20050261182-A1 | Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-6660885-B2 | Serine protease inhibitor | PHARMACIA CORPORATION | 2003-12-09 | — | — | US | disclosed |
| US-20020025947-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2002-02-28 | — | — | US | disclosed |
| EP-0314764-B2 | INJECTABLE OPACIFYING LIPOSOME COMPOSITION | DIBRA SPA (IT) | 2000-02-02 | — | — | EP | disclosed |
| US-5008288-A | Skeletal & heat muscle disorders | CEPTOR CORPORATION | 1991-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070224257-A1 | BRUCELLOSIS DNA VACCINE | CHMP4B, LRBA, TLR9 | OSBP 1065/4885RORC 3658/4885OSBP2 1639/4885 |
| US-20070155719-A1 | Platelet ADP receptor inhibitors | GP6, P2RY6, PIGS | OSBP 3891/4885RORC 4193/4885OSBP2 3504/4885 |
| US-20050261182-A1 | Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin | EPOR, SORD, STS | OSBP 2771/4885RORC 971/4885OSBP2 2685/4885 |
| US-20020025947-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | OSBP 4022/4885RORC 3686/4885OSBP2 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.